Équipe médicale de Raffles

Dr. Wu Bin, MD, PhD, is a Researcher and Postdoctoral Fellow at the Academy of Military Medical Sciences of the People's Liberation Army of China. With over three decades of experience, he has been engaged in both fundamental and clinical research on cell therapy and gene therapy for tumors and ischemic diseases. He serves as a principal investigator for biomedical projects under the National High Technology Research and Development Program ("863" Program) and the National Key Basic Research Program ("973" Program), and is a recipient of the Young Scientist Award from the International Union of Biological Sciences, in recognition of his pioneering contributions to cellular immunotherapy.

After earning his PhD in Internal Medicine/Hematology from the First Military Medical University in 2002, Dr. Wu pursued postdoctoral training at the Academy of Military Medical Sciences under the mentorship of Academician Wu Zuze, a renowned pathophysiologist and member of the Chinese Academy of Sciences. His research focuses on immune cells, stem cells, and gene therapy. Dr. Wu is proficient in clinical diagnosis and treatment of common and frequently occurring internal medicine diseases. His current main research directions include cell and gene therapy for tumors and ischemic diseases, such as combining immune cells with immune checkpoint inhibitors for treating malignant tumors; using genetically modified mesenchymal stem cells to treat cerebral ischemia, myocardial ischemia, limb ischemia, pulmonary fibrosis, and liver cirrhosis; and applying stem cell therapy in gynecology, health preservation, anti-aging, and aesthetic medicine. As the chief clinician within Academician Wu Zuze's research team, he has led collaborative projects with multiple clinical medical institutions.

The research projects Dr. Wu has led or participated in primarily include:

• National "863" Program-funded projects: Research on biological therapy for malignant tumors using recombinant adenovirus vectors carrying human wild-type p53, GM-CSF, and B7-1 genes;

• Gene therapy using human hepatocyte growth factor (HGF) for occlusive vascular diseases and pathological scarring; Studies on the role and mechanisms of the hepatocyte growth factor isoform HPPCn in liver regeneration and repair.

• National "Major New Drug Development" Program: Research on the draggability of recombinant HPPCn for treating acute and chronic liver injury.

• National Natural Science Foundation of China: Research on the mechanism of the sphingosine kinase signaling pathway in regulating abnormal bone marrow angiogenesis in chronic myeloid leukemia (CML).

He has authored over 40 papers in domestic and international academic journals.